Opaleye Management’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,460,000
| Closed | -$7.17M | – | 54 |
|
|
2021
Q3 | $7.17M | Sell |
1,460,000
-210,600
| -13% | -$1.02M | 1.34% | 24 |
|
|
2021
Q2 | $8.82M | Hold |
1,670,600
| – | – | 1.47% | 23 |
|
|
2021
Q1 | $8.02M | Buy |
1,670,600
+182,800
| +12% | +$955K | 1.18% | 25 |
|
|
2020
Q4 | $6.44M | Hold |
1,487,800
| – | – | 0.84% | 34 |
|
|
2020
Q3 | $6.13M | Buy |
1,487,800
+527,800
| +55% | +$2.04M | 1.2% | 29 |
|
|
2020
Q2 | $2.46M | Buy |
+960,000
| New | +$2.82M | 0.5% | 42 |
|
|
2017
Q3 | – | Sell |
-290,000
| Closed | -$5.07M | – | 43 |
|
|
2017
Q2 | $5.07M | Hold |
290,000
| – | – | 2.12% | 17 |
|
|
2017
Q1 | $5.08M | Buy |
290,000
+5,000
| +2% | +$85.2K | 2.53% | 16 |
|
|
2016
Q4 | $4.82M | Buy |
285,000
+35,000
| +14% | +$541K | 2.84% | 13 |
|
|
2016
Q3 | $4.1M | Sell |
250,000
-50,000
| -17% | -$760K | 2.15% | 19 |
|
|
2016
Q2 | $4.54M | Sell |
300,000
-20,000
| -6% | -$330K | 3.03% | 10 |
|
|
2016
Q1 | $6.06M | Buy |
320,000
+130,000
| +68% | +$2.19M | 3.78% | 7 |
|
|
2015
Q4 | $5.38M | Buy |
190,000
+24,300
| +15% | +$409K | 2.25% | 21 |
|
|
2015
Q3 | $2.77M | Buy |
165,700
+15,700
| +10% | +$357K | 1.37% | 30 |
|
|
2015
Q2 | $3.93M | Sell |
150,000
-105,000
| -41% | -$2.04M | 1.56% | 26 |
|
|
2015
Q1 | $4.46M | Buy |
+255,000
| New | +$4.37M | 2.07% | 22 |
|
Opaleye Management's ADMS Position: Q4 2021 in Review
Opaleye Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 1,460,000 shares — an estimated $7.17M sold.
Opaleye Management first reported a position in ADMS in Q1 2015 and held it in 16 quarters. The position peaked at $8.82M in Q2 2021. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Opaleye Management reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Opaleye Management sold 1,460,000 Adamas Pharmaceuticals shares in Q4 2021, an estimated $7.17M.
- Opaleye Management first reported a position in Adamas Pharmaceuticals in Q1 2015 and held it in 16 quarters.
- Opaleye Management's Adamas Pharmaceuticals position peaked at $8.82M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Opaleye Management's 13F filing for Q4 2021, filed 14 Feb 2022.